Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory ...

Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.

Ōtākou Whakaihu Waka researchers have been part of two studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis. Co-author on both studies, Dr.

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...

When researchers use an inhibitor to block a kinase’s activity, they generally expect to see less of the downstream effects of that kinase. So when neuroscientists observed the opposite using a new ...

The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic ...

A new Peter Mac study using a pioneering drug has successfully controlled the growth of tumors and overcome existing drug resistance in multiple cancer types. An enzyme critically associated with ...

Kerry Rogers, MD, weighs sequencing risk against daily adverse effects like bruising and joint pain that quietly influence BTK inhibitor decisions. On the selection side, Rogers explains why covalent ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

Share on Pinterest Scientists are studying treatments to reduce inflammation in Crohn’s disease and ulcerative colitis. Tom Werner/Getty Images Inflammatory bowel disease is a term that includes Crohn ...